📈💡 New and interesting player on the pharmaceutical market! 💊🔍
One of the most discussed topics in the pharmaceutical market is the treatment of obesity and diabetes. Only two companies are behind many successful drugs such asOzempic, Rybelsus and Saxenda: Novo Nordisk $NVO and Eli Lilly $LLY. These companies have had significant success in the treatment of diabetes and obesity with innovative agents such as semaglutide and tirzepatide.
However, a new player has now arrived on the scene , Viking Therapeutics $VKTX, and it could change the game. This biotech company is about to enter the fray with the well-known giants. With positive results from clinical trials for its VK2735, combining GLP-1 and GIP receptors, the company has seen its stock price soar.
There are currently two opportunities for the company. Thefirst option is to move quickly into Phase 3 trials and work with the FDA to bring the drug to market. The second option is a more interesting scenario in the form of anacquisition. Pfizer $PFE could be a potential suitor. Although Pfizer recently dove into the complicated Seagen acquisition and faces financial challenges, a potential acquisition of Viking could provide a boost to its existing portfolio.
What is your favorite pharmaceutical company?💉
For me, it's $PFEa-2.0% $LLY+0.7%.
$MRNA-1.5% has made little profit so far, but the expected results of studies this year give a decent chance for much more growth.